NCT06854653 2026-02-03
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Phase 2 Recruiting
Prescient Therapeutics, Ltd.
4SC AG
Genmab
Genmab
Novartis
Neumedicines Inc.
Merck Sharp & Dohme LLC
Angimmune LLC
Valerio Therapeutics